Psilocybin therapy is a supervised mental health treatment that combines a dose of psilocybin, the psychoactive compound in certain mushrooms, with structured psychological support before, during, and after the experience. Unlike taking an antidepressant daily, psilocybin therapy typically involves just one or two dosing sessions, paired with several hours of talk therapy spread across weeks. Early clinical trials have shown striking results: in one study comparing psilocybin to a common antidepressant for major depression, 57% of psilocybin patients achieved remission at six weeks, compared to 28% on the medication.
How Psilocybin Works in the Brain
Once ingested, psilocybin is converted in your body to psilocin, which is the compound that actually reaches the brain. Psilocin binds primarily to serotonin 2A receptors, the same type of serotonin receptor involved in mood, perception, and cognition. PET imaging studies have shown that a single dose can occupy up to 72% of these receptors in the outer brain, and the intensity of the psychedelic experience tracks closely with how many receptors are engaged. Higher receptor occupancy means a stronger experience.
This receptor activation appears to temporarily loosen rigid patterns of brain activity, particularly in networks responsible for your sense of self and habitual thinking. The result is a window of heightened psychological flexibility. People in clinical trials describe experiencing emotions, memories, and perspectives they normally keep walled off. The therapeutic value comes not just from the drug itself but from what a person does with that openness, which is where the therapy component becomes essential.
The Three Phases of Treatment
Psilocybin therapy follows a consistent three-phase structure across most clinical programs: preparation, dosing, and integration.
Preparation
Before the dosing session, you meet with a therapist multiple times over roughly three weeks. In clinical trials, a lead therapist handles most of these sessions, with a co-therapist joining for the final one. The goals are practical: getting comfortable with the range of experiences psilocybin can produce (which can include vivid imagery, intense emotions, or feelings of interconnectedness), setting personal intentions for the session, and developing strategies for handling difficult moments. Some patients also taper off existing psychiatric medications under a psychiatrist’s guidance during this period.
Dosing
The dosing session itself lasts several hours, typically in a calm, comfortable room with the therapist present throughout. Patients are encouraged to turn their attention inward, often wearing an eye mask and listening to music. The therapist doesn’t lead a traditional talk therapy session during this time. Instead, they provide a reassuring presence, offering guidance only when needed. Clinical trials have used doses ranging from 10 mg to 30 mg of psilocybin, with most therapeutic protocols using 25 mg as the standard high dose. Some trials use a weight-based approach, around 0.215 mg per kilogram of body weight. A second dosing session sometimes follows one to two weeks later.
Integration
After the dosing session, you return for another series of therapy sessions over approximately three weeks. The first integration session includes the co-therapist; later ones are typically one-on-one. Integration is where the therapeutic work solidifies. The goal is to make sense of what came up during the experience, translate any insights into concrete changes, and apply those shifts to daily life. Without this step, the experience risks becoming a vivid but ultimately disconnected event rather than a turning point.
What the Clinical Evidence Shows
The most compelling data so far comes from trials focused on depression. In an open-label study of treatment-resistant depression, 67% of patients reached remission one week after treatment, and 42% maintained remission at three months. A larger follow-up study for major depressive disorder found that 75% of participants responded to treatment and 58% were in remission at 12 months, with consistently large effect sizes at every follow-up point from one month through a full year.
Head-to-head comparisons are starting to emerge. In a double-blind trial pitting psilocybin against escitalopram (a widely prescribed SSRI) for major depression, remission rates at six weeks favored psilocybin: 57% versus 28%. Another trial found that a high dose produced remission in 60% of participants compared to 16% for a low dose at five weeks.
Psilocybin has also been studied in people with depression and anxiety related to cancer diagnoses. In one randomized trial, about 80% of participants continued to show clinically significant decreases in depressed mood and anxiety six months after treatment. These sustained effects from just one or two sessions are unusual in psychiatry, where most treatments require ongoing daily use.
That said, these trials have been relatively small, often involving dozens rather than hundreds of participants. Larger phase 3 trials are underway, and the results of those will determine whether psilocybin gains broader regulatory approval.
Who Should Not Receive Psilocybin Therapy
Not everyone is a candidate. Clinical trials have consistently excluded people with a personal or family history of psychotic disorders, including schizophrenia, schizoaffective disorder, and substance-induced psychosis. The concern is that psilocybin’s powerful effects on perception and thought could trigger or worsen psychotic symptoms in vulnerable individuals. People with bipolar disorder are also typically excluded due to the risk of manic episodes.
Other common exclusion criteria include borderline personality disorder, paranoid personality disorder, active substance use disorders, and a history of aggressive or suicidal behavior during psychotic episodes. Unstable physical health conditions can also be disqualifying, though the specifics vary by program. These restrictions exist because the safety data that supports psilocybin therapy was gathered from participants who didn’t have these conditions, so there’s simply not enough evidence to know what would happen.
Where It’s Legal in the United States
Psilocybin therapy is not yet approved by the FDA, but two states have created legal frameworks for supervised use. Oregon was first, and Colorado followed when Governor Jared Polis signed legislation in May 2023. Psilocybin remains a Schedule I substance under federal law, meaning these state programs exist in a legal gray area similar to early cannabis legalization.
Colorado’s system offers a useful picture of how regulated access works in practice. Two state agencies split oversight: the Department of Revenue licenses businesses (healing centers, cultivators, manufacturers, and testing facilities), while the Department of Regulatory Agencies licenses the facilitators who actually guide sessions. Healing centers must be owned by or contract with at least one licensed facilitator and can store more than 10 grams of dried mushrooms on site. A smaller “micro-healing center” license caps storage at about 10 grams and has lighter security requirements.
Facilitators licensed by the state can also conduct sessions outside of healing centers at certain approved locations, giving the system some flexibility. Anyone working in a healing center who handles psilocybin products needs a separate handler license. The practical effect is that legal psilocybin therapy in these states looks more like a visit to a specialized wellness center than a trip to a hospital or pharmacy. You go to a licensed location, work with a licensed facilitator, and the substance never leaves the supervised setting.
What the Experience Feels Like
People in clinical trials describe a wide range of experiences under psilocybin, from profound feelings of unity and emotional release to confronting painful memories or encountering fear and confusion. The experience typically lasts four to six hours, with the most intense period occurring roughly two to three hours after ingestion. Some participants cry, laugh, or sit in silence for long stretches. Others report visual imagery or a sensation of dissolving boundaries between themselves and their surroundings.
Difficult moments are common and not considered a sign that something has gone wrong. In the therapeutic framework, challenging emotions or unsettling imagery are treated as material to work through rather than side effects to suppress. This is a fundamental difference from most psychiatric treatment, where distressing symptoms are something to eliminate. In psilocybin therapy, the distress can be part of the mechanism. The preparation phase is designed partly to help you navigate these moments, and the integration phase is where you make meaning of them.